MarketPulse

PALISADE-3

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Therapeutics Faces Securities Class Action Over Drug Trial Disclosure Allegations

Rosen Law Firm announces March 16, 2026 deadline for investors to join securities class action against Vistagen Therapeutics ($VTGN) over alleged misleading statements regarding fasedienol drug trial.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Vistagen Investors Face Class Action Deadline Following Failed Phase 3 Trial

Vistagen faces class action lawsuit after Phase 3 trial failure for anxiety drug. Stock plunged 80%. Investors must act by March 16, 2026 deadline.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Legal Action Deadline Set for Vistagen Investors Following Failed Trial

Vistagen's failed drug trial caused 81% stock drop. Securities lawsuit filed for investors who bought shares April 2024-December 2025. Lead plaintiff deadline: March 16, 2026.
VTGNsecurities class actionmisleading statements